{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:32:11Z","timestamp":1792740731752,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s40265-017-0828-8","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T04:13:32Z","timestamp":1509509612000},"page":"1881-1896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix\u00ae): A Review"],"prefix":"10.1007","volume":"77","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"828_CR1","unstructured":"WHO. Meningococcal meningitis: fact sheet no. 141. 2017. http:\/\/www.who.int\/mediacentre\/factsheets\/fs141\/en\/. Accessed 13 Oct 2017."},{"issue":"1","key":"828_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1478-7954-11-17","volume":"11","author":"RZ Jafri","year":"2013","unstructured":"Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17.","journal-title":"Popul Health Metr."},{"issue":"4","key":"828_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3201\/eid1904.111799","volume":"19","author":"OB Harrison","year":"2013","unstructured":"Harrison OB, Claus H, Jiang Y, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19(4):566\u201373.","journal-title":"Emerg Infect Dis"},{"issue":"2 Suppl","key":"828_CR4","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","volume":"59","author":"SI Pelton","year":"2016","unstructured":"Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2 Suppl):S3\u201311.","journal-title":"J Adolesc Health"},{"key":"828_CR5","unstructured":"Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs) report emerging infections program network: Neisseria meningitidis. 2015. https:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/mening15.pdf. Accessed 13 Oct 2017."},{"issue":"7","key":"828_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1179\/2047773213Y.0000000119","volume":"107","author":"A Abio","year":"2013","unstructured":"Abio A, Neal KR, Beck CR. An epidemiological review of changes in meningococcal biology during the last 100 years. Pathog Glob Health. 2013;107(7):373\u201380.","journal-title":"Pathog Glob Health."},{"issue":"12","key":"828_CR7","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.4161\/hv.21794","volume":"8","author":"M Broker","year":"2012","unstructured":"Broker M, Jacobsson S, Kuusi M, et al. Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother. 2012;8(12):1907\u201311.","journal-title":"Hum Vaccin Immunother."},{"issue":"4","key":"828_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/cid\/ciu881","volume":"60","author":"SN Ladhani","year":"2015","unstructured":"Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578\u201385.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"828_CR9","first-page":"1825","volume":"12","author":"A Assaf-Casals","year":"2016","unstructured":"Assaf-Casals A, Dbaibo G. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix\u2122): a review of its immunogenicity, safety, co-administration, and antibody persistence. Hum Vaccin Immunother. 2016;12(7):1825\u201337.","journal-title":"Hum Vaccin Immunother."},{"issue":"5","key":"828_CR10","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/S0022-3476(78)80165-6","volume":"92","author":"H Peltola","year":"1978","unstructured":"Peltola H, Kayhty H, Kuronen T, et al. Meningococcus group A vaccine in children three months to five years of age. Adverse reactions and immunogenicity related to endotoxin content and molecular weight of the polysaccharide. J Pediatr. 1978;92(5):818\u201322.","journal-title":"J Pediatr"},{"issue":"9580","key":"828_CR11","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","volume":"369","author":"DS Stephens","year":"2007","unstructured":"Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196\u2013210.","journal-title":"Lancet"},{"issue":"12","key":"828_CR12","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/j.1365-3156.2007.01929.x","volume":"12","author":"S Dellicour","year":"2007","unstructured":"Dellicour S, Greenwood B. Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health. 2007;12(12):1409\u201321.","journal-title":"Trop Med Int Health."},{"issue":"12","key":"828_CR13","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.4161\/hv.26109","volume":"9","author":"ME Pichichero","year":"2013","unstructured":"Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother. 2013;9(12):2505\u201323.","journal-title":"Hum Vaccin Immunother."},{"key":"828_CR14","unstructured":"European Medicines Agency. Nimenrix: summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002226\/WC500127663.pdf. Accessed 13 Oct 2016."},{"key":"828_CR15","unstructured":"Pfizer Inc. Pfizer receives approval in the European Union for Nimenrix\u2122 (meningococcal group A, C, W-135, and Y conjugate vaccine) in infants six weeks of age and older [media release]. 19 Dec 2016. http:\/\/press.pfizer.com\/press-release\/pfizer-receives-approval-european-union-nimenrix-meningococcal-group-c-w-135-and-y-con."},{"key":"828_CR16","doi-asserted-by":"publisher","first-page":"35588","DOI":"10.1038\/srep35588","volume":"6","author":"AS Abdelhameed","year":"2016","unstructured":"Abdelhameed AS, Morris GA, Almutairi F, et al. Solution conformation and flexibility of capsular polysaccharides from Neisseria meningitidis and glycoconjugates with the tetanus toxoid protein. Sci Rep. 2016;6:35588.","journal-title":"Sci Rep."},{"key":"828_CR17","unstructured":"European Medicines Agency. Nimenrix: assessment report (EMEA\/H\/C\/000113\/P46\/0017). 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/002226\/WC500144738.pdf. Accessed 13 Oct 2017."},{"issue":"17\u201318","key":"828_CR18","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","author":"R Borrow","year":"2005","unstructured":"Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection: serum bactericidal antibody activity. Vaccine. 2005;23(17\u201318):2222\u20137.","journal-title":"Vaccine."},{"issue":"5","key":"828_CR19","first-page":"780","volume":"10","author":"N Andrews","year":"2003","unstructured":"Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10(5):780\u20136.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"4","key":"828_CR20","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1097\/INF.0000000000001484","volume":"36","author":"JM Merino Arribas","year":"2016","unstructured":"Merino Arribas JM, Carmona Martinez A, Horn M, et al. Safety and immunogenicity of the quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine co-administered with routine childhood vaccines in European infants: an open, randomized trial. Pediatr Infect Dis J. 2016;36(4):e98\u2013107.","journal-title":"Pediatr Infect Dis J."},{"key":"828_CR21","unstructured":"European Medicines Agency. Nimenrix: assessment report (EMEA\/H\/C\/002226\/II\/0049). 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/002226\/WC500220577.pdf. Accessed 13 Oct 2017."},{"issue":"25","key":"828_CR22","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","volume":"29","author":"T Vesikari","year":"2011","unstructured":"Vesikari T, Karvonen A, Bianco V, et al. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine. 2011;29(25):4274\u201384.","journal-title":"Vaccine."},{"issue":"25","key":"828_CR23","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","volume":"29","author":"M Knuf","year":"2011","unstructured":"Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine. 2011;29(25):4264\u201373.","journal-title":"Vaccine."},{"issue":"7","key":"828_CR24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/INF.0b013e31828693c5","volume":"32","author":"NP Klein","year":"2013","unstructured":"Klein NP, Baine Y, Bianco V, et al. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. Pediatr Infect Dis J. 2013;32(7):760\u20137.","journal-title":"Pediatr Infect Dis J."},{"key":"828_CR25","unstructured":"GlaxoSmithKline. 116892 scientific result summary. 2016. https:\/\/www.gsk-clinicalstudyregister.com\/files2\/116892%20-%20Clinical-Study-Result-Summary.pdf. Accessed 13 Oct 2017."},{"issue":"1","key":"828_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","volume":"30","author":"CJ Gill","year":"2011","unstructured":"Gill CJ, Ram S, Welsch JA, et al. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source. Vaccine. 2011;30(1):29\u201334.","journal-title":"Vaccine."},{"issue":"29","key":"828_CR27","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1016\/j.vaccine.2016.05.009","volume":"34","author":"G Bona","year":"2016","unstructured":"Bona G, Castiglia P, Zoppi G, et al. Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers. Vaccine. 2016;34(29):3363\u201370.","journal-title":"Vaccine."},{"issue":"4","key":"828_CR28","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","volume":"30","author":"ZA Memish","year":"2011","unstructured":"Memish ZA, Dbaibo G, Montellano M, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J. 2011;30(4):e56\u201362.","journal-title":"Pediatr Infect Dis J."},{"issue":"5","key":"828_CR29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00431-012-1924-0","volume":"172","author":"M Knuf","year":"2013","unstructured":"Knuf M, Romain O, Kindler K, et al. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study. Eur J Pediatr. 2013;172(5):601\u201312.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"828_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4161\/hv.7.2.14068","volume":"7","author":"N Bermal","year":"2011","unstructured":"Bermal N, Huang LM, Dubey AP, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin. 2011;7(2):239\u201347.","journal-title":"Hum Vaccin."},{"issue":"5","key":"828_CR31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40266-013-0065-0","volume":"30","author":"G Dbaibo","year":"2013","unstructured":"Dbaibo G, El-Ayoubi N, Ghanem S, et al. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56\u00a0years and older: results of an open-label, randomized, controlled trial. Drugs Aging. 2013;30(5):309\u201319.","journal-title":"Drugs Aging"},{"issue":"7","key":"828_CR32","doi-asserted-by":"publisher","first-page":"873","DOI":"10.4161\/hv.20211","volume":"8","author":"G Dbaibo","year":"2012","unstructured":"Dbaibo G, Macalalad N, Aplasca-De Los Reyes MR, et al. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study. Hum Vaccin Immunother. 2012;8(7):873\u201380.","journal-title":"Hum Vaccin Immunother."},{"issue":"11","key":"828_CR33","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1097\/INF.0000000000000866","volume":"34","author":"R Baxter","year":"2015","unstructured":"Baxter R, Baine Y, Kolhe D, et al. Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial. Pediatr Infect Dis J. 2015;34(11):1236\u201343.","journal-title":"Pediatr Infect Dis J."},{"issue":"1","key":"828_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/21645515.2015.1058457","volume":"12","author":"T Vesikari","year":"2016","unstructured":"Vesikari T, Forsten A, Bianco V, et al. Antibody persistence up to 5\u00a0years after vaccination of toddlers and children between 12\u00a0months and 10\u00a0years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum Vaccin Immunother. 2016;12(1):132\u20139.","journal-title":"Hum Vaccin Immunother."},{"issue":"6","key":"828_CR35","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/INF.0000000000001123","volume":"35","author":"NP Klein","year":"2016","unstructured":"Klein NP, Baine Y, Kolhe D, et al. Five-year antibody persistence and booster response after 1 or 2 doses of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in healthy children. Pediatr Infect Dis J. 2016;35(6):662\u201372.","journal-title":"Pediatr Infect Dis J."},{"issue":"7","key":"828_CR36","doi-asserted-by":"publisher","first-page":"866","DOI":"10.4161\/hv.20229","volume":"8","author":"M Knuf","year":"2012","unstructured":"Knuf M, Baine Y, Bianco V, et al. Antibody persistence and immune memory 15\u00a0months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. Hum Vaccin Immunother. 2012;8(7):866\u201372.","journal-title":"Hum Vaccin Immunother."},{"issue":"12","key":"828_CR37","doi-asserted-by":"publisher","first-page":"e298","DOI":"10.1097\/INF.0000000000000897","volume":"34","author":"T Vesikari","year":"2015","unstructured":"Vesikari T, Forsten A, Bianco V, et al. Immunogenicity, safety and antibody persistence of a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine compared with monovalent meningococcal serogroup C vaccine administered four years after primary vaccination using the same vaccines. Pediatr Infect Dis J. 2015;34(12):e298\u2013307.","journal-title":"Pediatr Infect Dis J."},{"key":"828_CR38","unstructured":"GlaxoSmithKline. 113977 scientific result summary. 2015. https:\/\/www.gsk-clinicalstudyregister.com\/files2\/d0424121-e9e2-4274-8b5d-887bcb757aad. Accessed 13 Oct 2017."},{"issue":"3","key":"828_CR39","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","volume":"30","author":"R Baxter","year":"2011","unstructured":"Baxter R, Baine Y, Ensor K, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25\u00a0years of age. Pediatr Infect Dis J. 2011;30(3):e41\u20138.","journal-title":"Pediatr Infect Dis J."},{"issue":"8","key":"828_CR40","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1097\/INF.0000000000000750","volume":"34","author":"DA Ishola","year":"2015","unstructured":"Ishola DA, Andrews N, Waight P, et al. Randomized trial to compare the immunogenicity and safety of a CRM or TT conjugated quadrivalent meningococcal vaccine in teenagers who received a CRM or TT conjugated serogroup C vaccine at preschool age. Pediatr Infect Dis J. 2015;34(8):865\u201374.","journal-title":"Pediatr Infect Dis J."},{"key":"828_CR41","unstructured":"Public Health England. Meningococcal ACWY immunisation programme for adolescents: information for healthcare professionals. 2016. https:\/\/www.gov.uk\/government\/publications\/menacwy-programme-information-for-healthcare-professionals. Accessed 13 Oct 2017."},{"issue":"9960","key":"828_CR42","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","volume":"384","author":"RC Read","year":"2014","unstructured":"Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123\u201331.","journal-title":"Lancet"},{"issue":"8","key":"828_CR43","doi-asserted-by":"publisher","first-page":"e608","DOI":"10.1016\/j.ijid.2012.04.006","volume":"16","author":"G Dbaibo","year":"2012","unstructured":"Dbaibo G, Van der Wielen M, Reda M, et al. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. Int J Infect Dis. 2012;16(8):e608\u201315.","journal-title":"Int J Infect Dis."},{"issue":"4","key":"828_CR44","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.vaccine.2011.11.051","volume":"30","author":"L \u00d8stergaard","year":"2012","unstructured":"\u00d8stergaard L, Silfverdal SA, Berglund J, et al. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix\u00ae in subjects aged 11-17\u00a0years: an open, randomised, controlled trial. Vaccine. 2012;30(4):774\u201383.","journal-title":"Vaccine."},{"issue":"7","key":"828_CR45","doi-asserted-by":"publisher","first-page":"881","DOI":"10.4161\/hv.20212","volume":"8","author":"MR Aplasca-De Los Reyes","year":"2012","unstructured":"Aplasca-De Los Reyes MR, Dimaano E, Macalalad N, et al. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Hum Vaccin Immunother. 2012;8(7):881\u20137.","journal-title":"Hum Vaccin Immunother."},{"issue":"1","key":"828_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/INF.0b013e3182784143","volume":"32","author":"GM Ruiz-Palacios","year":"2013","unstructured":"Ruiz-Palacios GM, Huang LM, Lin TY, et al. Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial. Pediatr Infect Dis J. 2013;32(1):62\u201371.","journal-title":"Pediatr Infect Dis J."},{"key":"828_CR47","unstructured":"European Centre for Disease Prevention and Control. Vaccine schedule: recommended immunisations for meningococcal disease. 2017. http:\/\/vaccine-schedule.ecdc.europa.eu\/Pages\/Scheduler.aspx. Accessed 13 Oct 2017."},{"key":"828_CR48","unstructured":"Public Health England. Meningococcal: the green book, chapter 22. 2016. https:\/\/www.gov.uk\/government\/publications\/meningococcal-the-green-book-chapter-22. Accessed 13 Oct 2017."},{"issue":"4","key":"828_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","volume":"16","author":"R Borrow","year":"2017","unstructured":"Borrow R, Alarcon P, Carlos J, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16(4):313\u201328.","journal-title":"Expert Rev Vaccines."},{"issue":"Pt 7","key":"828_CR50","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","volume":"55","author":"SJ Gray","year":"2006","unstructured":"Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the meningococcal reference unit. J Med Microbiol. 2006;55(Pt 7):887\u201396.","journal-title":"J Med Microbiol"},{"key":"828_CR51","unstructured":"Public Health England. Removal of the infant dose of meningococcal serogroup C (MenC) conjugate vaccine given at three months from 1 July 2016. 2016. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/512311\/2016_MenC_infant_schedule_letter-FINAL__1_.pdf. Accessed 13 Oct 2017."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-017-0828-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0828-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0828-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:49:19Z","timestamp":1659113359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-017-0828-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":51,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["828"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0828-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"1 November 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sohita Dhillon is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest. David Pace has no conflict of interest to declare.Additional information about this Adis Drug Review can be found at .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}